Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial - Loomba, R; Abdelmalek, M F; Armstrong, M J (Lancet Gastroenterol Hepatol, 2023)